Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Date:4/21/2009

- Safety and Tumor Response Data from Dose-Escalation Study Presented at

American Association for Cancer Research's 100th Annual Meeting 2009 -

SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated that picoplatin can be safely administered in combination with 5-fluorouracil and leucovorin (FOLPI) as a first-line option for CRC. Based on the safety data as well as the promising clinical activity observed in this trial, Poniard initiated a randomized, controlled, proof-of-concept Phase 2 trial to evaluate picoplatin as a neuropathy-sparing alternative to oxaliplatin for the first-line treatment of metastatic CRC. Patient enrollment was completed in May 2008.

"Several treatment options for metastatic CRC have been introduced in the last decade and have resulted in enhanced survival when administered as a first-line treatment. However, these treatments can cause serious side effects, including severe neuropathies that prevent patients from participating in routine daily activities and may lead to discontinuing therapy," said Robert De Jager, M.D., chief medical officer of Poniard. "We are encouraged by these preliminary results, which continue to show that picoplatin given once every four weeks as part of the FOLPI regimen is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen; both regimens have similar anti-tumor activity in first-line metastatic CRC. We are continuing to observe the study participants and look forward to presenting initial pro
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
2. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
3. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
4. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
5. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
8. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
9. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
10. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
11. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  AMRI (NASDAQ: AMRI ) announced ... , site has received approval to expand its ... handle Schedule 2 and 2N controlled substances. The ... Burlington,s physical security and quality systems, ... http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With its ...
(Date:6/18/2013)... , June 18, 2013 Mapi Pharma ... generic and innovative intermediates, and finished dosage forms based on ... been granted a United States patent ... Europe for the oral treatment of moderate-to-severe ... titled Intermediate Compounds and Processes for the Preparation of ...
(Date:6/18/2013)... 2013 This webinar will examine ... and promotion, and review the basic FDA regulations ... to apply these principles through real world case ...     The fundamentals on FDA regulations and guidance related ...     Assessing traditional and newer forms of promotional ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 /PRNewswire/ ... http://www.researchandmarkets.com/research/4b8vj2/injectable_drug ) has announced the addition of ... Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables ... Free & Auto Injectors] & Therapeutics [Diabetes ... report to their offering. ...
Breaking Biology Technology:AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3
... ,,,,, PfuTurbo DNA ... Pfx DNA polymerase , Michael ... recently evaluated the properties of Platinum ,Pfx DNA ... polymerase and polymerase-specific antibodies. Comparisons,revealed that Stratagenes PfuTurbo ...
... cDNA Library Array I ,, Over 145,000 human cDNA clones arrayed for nucleic ... Jean-Michel Llias Leonardo de Leon Bruce Jerpseth , ... Stratagene , Stratagene has organized over ... cDNA library that represent genes expressed in 29 different human tissues. , ...
... cloning kits feature new additions , Tim Sanchez ... kits are convenient for cloning,PCR fragments generated ... easy, and superior to other available methods. 3 Now,Stratagene ... , PCR purification kit, so preparing PCR products is ...
Cached Biology Technology:Comparing Fidelity and Performance of Proofreading PCR Enzymes 2Comparing Fidelity and Performance of Proofreading PCR Enzymes 3Comparing Fidelity and Performance of Proofreading PCR Enzymes 4Comparing Fidelity and Performance of Proofreading PCR Enzymes 5Comparing Fidelity and Performance of Proofreading PCR Enzymes 6Comparing Fidelity and Performance of Proofreading PCR Enzymes 7Comparing Fidelity and Performance of Proofreading PCR Enzymes 8Human Universal cDNA Library Array I 2Human Universal cDNA Library Array I 3Human Universal cDNA Library Array I 4Human Universal cDNA Library Array I 5Human Universal cDNA Library Array I 6Human Universal cDNA Library Array I 7Enhanced PCR Cloning System 2Enhanced PCR Cloning System 3Enhanced PCR Cloning System 4
(Date:6/17/2013)... MANHATTAN, KAN. -- A Kansas State University research associate ... on mosquitoes and ways to prevent the spread of ... received the National Institutes of Health,s National Research Service ... years. He is the seventh Kansas State University researcher ... on campus to currently hold such an award. , ...
(Date:6/17/2013)... method of mining shale gas, is widespread across Pennsylvania, ... New research in the Annals of the New ... to biodiversity including pollution from toxic chemicals, the building ... , "Shale gas has engendered a great deal of ... but effects on biological diversity and resources have scarcely ...
(Date:6/16/2013)... A mechanism that cells use to group together and move ... been described for the first time by scientists at UCL. ... new study focuses on the process that occurs when cancer ... the body during metastasis. Scientists know that cancer cells recruit ... how this process takes place and how it could be ...
Breaking Biology News(10 mins):NIH fellowship helps researcher fight malaria, understand mosquito immunity 2'Chase and run' cell movement mechanism explains process of metastasis 2
... realizing that the potential for bioterrorism isn,t just about ... introduction of bacteria, a virus or a toxin could ... issuing a paper aimed at prevention. "Any emerging ... trade needs to be aware of the potential for ...
... an elusive gene responsible for Gray Platelet Syndrome, an extremely ... have been reported. As a result, it is hoped that ... test. The findings were made following a collaborative study ... both based at the Wellcome Trust Sanger Institute and the ...
... do a herd of gazelles and a fluffy mass ... describes the population dynamics of such prey animals as ... the relationship between cloud systems, rain and tiny floating ... understand, among other things, how human-produced aerosols affect rainfall ...
Cached Biology News:Global bioterrorism threat analyzed for world animal health office 2Anglo-French team discover elusive gene that makes platelets gray 2Anglo-French team discover elusive gene that makes platelets gray 3Anglo-French team discover elusive gene that makes platelets gray 4Eat, prey, rain 2
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Request Info...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Biology Products: